<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03594604</url>
  </required_header>
  <id_info>
    <org_study_id>040818M1</org_study_id>
    <nct_id>NCT03594604</nct_id>
  </id_info>
  <brief_title>Norethindrone for the Delay of Menstruation</brief_title>
  <official_title>Norethindrone Versus Combined Oral Contraceptive Pills for the Delay of Menstruation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wayne State University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wayne State University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Comparison of oral contraceptive pills versus norethindrone to delay menstuation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Many women ask the OBGYN for help in delaying a poorly timed period in order to participate
      in events that menstruation would normally interfere with. While most OBGYNs prescribe
      combined oral contraceptives for this purpose, this method often results in unpredictable
      spotting, especially at the beginning of therapy. Norethindrone, a progesterone agonist,
      inhibits ovulation through its antagonistic effect at the anterior pituitary, preventing the
      release of LH. Additionally, it thickens cervical mucus to inhibit sperm migration into the
      uterine cavity . Norethindrone downregulates estrogen receptors on the endometrium lining
      preventing endometrial proliferation, enhancing glandular secretion, and maintaining
      endometrium integrity. Therefore, norethindrone is well suited in preventing the endometrium
      from breakdown and preventing menstrual bleeding. Indeed, many OBGYNs have consistently used
      it for this purpose in women who desire to remain fertile. The intention of our study was to
      compare norethindrone to birth control pills in order to determine the effectiveness at
      suppressing bleeding and spotting, compare side effect profiles and to find a method allowing
      women to freely and comfortably participate in their life events.

      OBJECTIVES:

        1. Determine if norethindrone can delay menstruation without breakthrough bleeding

        2. Compare norethindrone with oral contraceptive pills for delaying menstruation

        3. Compare patient satisfaction of each method

        4. Compare side effect profiles of each method
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 15, 2007</start_date>
  <completion_date type="Actual">December 15, 2007</completion_date>
  <primary_completion_date type="Actual">December 15, 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients will be randomized to receive oral contraceptive pills or norethindrone</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Investigator)</masking>
    <masking_description>Patients will be randomized to receive oral contraceptive pills or norethindrone</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>breakthrough bleeding on treatment</measure>
    <time_frame>at 2 weeks from starting therapy</time_frame>
    <description>comparison of breakthrough bleeding between oral contraceptives and norethindrone</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Likelihood of recommending this method or using it again</measure>
    <time_frame>at 2 weeks from starting therapty</time_frame>
    <description>A questionnaire given to the patient at 2 weeks from starting therapy and containing the question &quot;on a scale from 1-5 (5 most likely) how likely are you to recommend this method to a friend or using it again yourself&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse effects</measure>
    <time_frame>at 2 weeks from starting therapy</time_frame>
    <description>measurement of side effects from norethindrone therapy</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Menstrual Flow Altered</condition>
  <arm_group>
    <arm_group_label>Norethindrone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Delaying menstruation using Norethindrone 5mg three times daily in women who desire postponement of their period for social or personal reasons.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral Contraceptive Pills</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Women who desire postponing their periods are typically treated with oral contraceptive pills, the current standard of care.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Norethindrone</intervention_name>
    <description>Women desiring to postpone their periods may be randomized to norethindrone 5mg three times daily.</description>
    <arm_group_label>Norethindrone</arm_group_label>
    <other_name>(Aygestin)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oral contraceptive pill</intervention_name>
    <description>Women desiring to postpone their periods may be randomized to daily oral contraceptive pills.</description>
    <arm_group_label>Oral Contraceptive Pills</arm_group_label>
    <other_name>Combined oral contraceptive pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  female, age 18-45, regular periods, desires to postpone menstrual period,

        Exclusion Criteria:

          -  fibroids, irregular menstrual cycle, endometrial polyps, BMI&gt;30
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Only females menstruate</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maurice Recanati</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Vincents Catholic Medical Centers</affiliation>
  </overall_official>
  <reference>
    <citation>Attia AM, Ibrahim MM, Abou-Setta AM. Role of the levonorgestrel intrauterine system in effective contraception. Patient Prefer Adherence. 2013 Aug 9;7:777-85. doi: 10.2147/PPA.S36948. eCollection 2013.</citation>
    <PMID>23990713</PMID>
  </reference>
  <results_reference>
    <citation>Yairi-Oron Y, Rabinson J, Orvieto R. A simplified approach to religious infertility. Fertil Steril. 2006 Dec;86(6):1771-2. Epub 2006 Oct 30.</citation>
    <PMID>17074351</PMID>
  </results_reference>
  <results_reference>
    <citation>Chertok IR, Zimmerman DR, Taragin S, Silverman Z, Hallak M. Implications of endometriosis for women who observe Jewish law (halakha). Isr Med Assoc J. 2005 Feb;7(2):71-4. Review.</citation>
    <PMID>15729953</PMID>
  </results_reference>
  <results_reference>
    <citation>Amy JJ, Tripathi V. Contraception for women: an evidence based overview. BMJ. 2009 Aug 7;339:b2895. doi: 10.1136/bmj.b2895. Review.</citation>
    <PMID>19666684</PMID>
  </results_reference>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>June 18, 2018</study_first_submitted>
  <study_first_submitted_qc>July 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 20, 2018</study_first_posted>
  <last_update_submitted>July 18, 2018</last_update_submitted>
  <last_update_submitted_qc>July 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Wayne State University</investigator_affiliation>
    <investigator_full_name>Maurice-Andre Recanati</investigator_full_name>
    <investigator_title>Assistant Professor, Clinical Educator</investigator_title>
  </responsible_party>
  <keyword>norethindrone</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Contraceptive Agents</mesh_term>
    <mesh_term>Norethindrone</mesh_term>
    <mesh_term>Norethindrone Acetate</mesh_term>
    <mesh_term>Contraceptives, Oral</mesh_term>
    <mesh_term>Contraceptives, Oral, Combined</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

